Your browser doesn't support javascript.
Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Rognvaldsson, Saemundur; Eythorsson, Elias; Thorsteinsdottir, Sigrun; Vidarsson, Brynjar; Onundarson, Pall Torfi; Agnarsson, Bjarni A; Sigurdardottir, Margret; Thorsteinsdóttir, Ingunn; Olafsson, Isleifur; Runolfsdottir, Hrafnhildur L; Helgason, Dadi; Emilsdottir, Arna R; Agustsson, Arnar S; Bjornsson, Aron H; Kristjansdottir, Gudrun; Thordardottir, Asdis Rosa; Indridason, Olafur Skuli; Jonsson, Asbjorn; Gislason, Gauti Kjartan; Olafsson, Andri; Steingrimsdottir, Hlif; Kampanis, Petros; Hultcrantz, Malin; Durie, Brian G M; Harding, Stephen; Landgren, Ola; Palsson, Runolfur; Love, Thorvarður Jon; Kristinsson, Sigurdur Yngvi.
  • Rognvaldsson S; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Eythorsson E; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Thorsteinsdottir S; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Vidarsson B; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Onundarson PT; Rigshospitalet, Copenhagen, Denmark.
  • Agnarsson BA; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Sigurdardottir M; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Thorsteinsdóttir I; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Olafsson I; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Runolfsdottir HL; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Helgason D; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Emilsdottir AR; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Agustsson AS; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Bjornsson AH; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Kristjansdottir G; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Thordardottir AR; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Indridason OS; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Jonsson A; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Gislason GK; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Olafsson A; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Steingrimsdottir H; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Kampanis P; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Hultcrantz M; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Durie BGM; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Harding S; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Landgren O; Akureyri Hospital, Akureyri, Iceland.
  • Palsson R; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Love TJ; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Kristinsson SY; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland.
Blood Cancer J ; 11(12): 191, 2021 12 01.
Article in English | MEDLINE | ID: covidwho-1545601
ABSTRACT
Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR) 1.05; 95% confidence interval (CI) 0.81-1.36; p = 0.72) or severe COVID-19 (OR 0.99; 95%CI 0.52-1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Monoclonal Gammopathy of Undetermined Significance / COVID-19 Type of study: Etiology study / Incidence study / Observational study / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Blood Cancer J Year: 2021 Document Type: Article Affiliation country: S41408-021-00580-7

Full text: Available Collection: International databases Database: MEDLINE Main subject: Monoclonal Gammopathy of Undetermined Significance / COVID-19 Type of study: Etiology study / Incidence study / Observational study / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Blood Cancer J Year: 2021 Document Type: Article Affiliation country: S41408-021-00580-7